Lactic acid bacteria in the gastrointestinal tract: Anti-helicobacter pylori
Issued Date
2024-06-03
Resource Type
Scopus ID
2-s2.0-85197608538
Journal Title
Advances in Biology
Volume
6
Start Page
37
End Page
64
Rights Holder(s)
SCOPUS
Bibliographic Citation
Advances in Biology Vol.6 (2024) , 37-64
Suggested Citation
Techo S., Kingkaew E., Tanasupawat S. Lactic acid bacteria in the gastrointestinal tract: Anti-helicobacter pylori. Advances in Biology Vol.6 (2024) , 37-64. 64. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99652
Title
Lactic acid bacteria in the gastrointestinal tract: Anti-helicobacter pylori
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Numerous bacterial species have been found throughout the human GI tract, which consists of the oral cavity, stomach, intestine, and colon. Lactic acid bacteria (LAB), including Lactobacillus (L. ) acidophilus, L. salivarius, L. johnsonii, L. crispatus, L. casei, L. paracasei, L. rhamnosus, L. reuteri, L. oris, L. vaginalis, L. gasseri, L. plantarum, L. buchneri, L. mali, L. ruminis, L. delbrueckii, L. sakei, L. fermentum, L. helviticus, and L. brevis ; Streptococcus ( S. ) salivarius, S. pneumonia, S. mitis, S. oralis, S. parasanguinis, S. anginosus, S. constellatus, S. caprinus, and S. mutans ; Leuconostoc (Ln. ) mesenteroides and Ln. argentinum ; Lactococcus (Lc.) lactis; and Enterococcus (En. ) strains, are distributed throughout the human GI tract. The bacterial microbiota in humans changes when infected with Helicobacter (H. ) pylori. Moreover, antibiotics and proton pump inhibitors (PPIs) used in the regimen influence microbial microbiota. However, alteration of bacterial diversity is rather complicated and has conflicting effects. To maintain microbial balance in the GI tract, several studies have used probiotics as adjunctive therapy to reduce the number of H. pylori in infected humans, replacing antibiotics alone. Probiotics have shown a higher eradication rate of H. pylori when compared with antibiotics alone. Bacteriocin production by LAB is one of the interesting mechanisms that can inhibit the growth of H. pylori. Bacteriocins and bacteriocin-like substances exhibiting antibacterial properties against H. pylori have been reported. These active peptides could be exploited to develop novel therapeutics for treating H. pylori infection.